TDC
TECX

Thompson Davis & Co’s Tectonic Therapeutic TECX Stock Holding History

Thompson Davis & Co’s Portfolio TECX Stock Details TECX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-162
Closed -$55K – 797
2018
Q2 		$55K Buy
+162
New +$58.4K 0.13% 173

Other funds holding TECX

CV
Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Thompson Davis & Co's TECX Position: Q3 2018 in Review

Thompson Davis & Co sold out of Tectonic Therapeutic (TECX) in Q3 2018, closing a stake of 162 shares — an estimated $55K sold.

Thompson Davis & Co first reported a position in TECX in Q2 2018 and held it in 1 quarter. The position peaked at $55K in Q2 2018. 63 funds tracked by Wall St. Rank hold TECX as of Q3 2018.

  • Thompson Davis & Co reported no remaining Tectonic Therapeutic position as of Q3 2018 after selling out during the quarter.
  • Thompson Davis & Co sold 162 Tectonic Therapeutic shares in Q3 2018, an estimated $55K.
  • Thompson Davis & Co first reported a position in Tectonic Therapeutic in Q2 2018 and held it in 1 quarter.
  • Thompson Davis & Co's Tectonic Therapeutic position peaked at $55K in Q2 2018.
  • 63 funds tracked by Wall St. Rank held Tectonic Therapeutic as of Q3 2018.

Based on Thompson Davis & Co's 13F filing for Q3 2018, filed 14 Nov 2018.